Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN FRANCISCO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
-
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the...
-
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
-
SAN FRANCISCO, Feb. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
-
SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
-
SAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
-
SAN FRANCISCO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
-
SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
-
SAN FRANCISCO, Jan. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
-
SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...